Scienture Holdings, Inc. - Common Stock (SCNX)

Let's have a look at what is happening on the US markets one hour before the close of the markets on Friday. Below you can find the top gainers and losers in today's session.

Volume analysis on 2025-10-24: stocks with an unusual volume in today's session.

Keep an eye on the top gainers and losers in Friday's session, as they reflect the most notable price movements.

Let's delve into the US markets on Friday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.

The US market is yet to commence its session on Friday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.

Major U.S. indices closed higher on Thursday, with the Dow Jones Industrial Average up 0.3% at 46,734.61, the S&P 500 advancing nearly 0.6% to 6,738.44.

Intrigued by the market activity one hour before the close of the markets on Thursday? Uncover the key winners and losers of today's session in our insightful analysis.

Discover the most active stocks in Thursday's session. Stay informed about the stocks that are generating the most trading volume!

Shares of Scienture Holdings, Inc. (NASDAQ: SCNX) are rising Thursday after the company announced the start of commercial sales for Arbli.

Let's have a look at the stocks with an unusual volume in today's session.

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Scienture has commenced selling Arbli, the first FDA-approved ready-to-use liquid losartan formulation.

The market is buzzing with gapping stocks on Thursday. Let's uncover which stocks are experiencing notable gaps during today's session.

Discover the top movers in Thursday's pre-market session and stay informed about market dynamics.

Scienture launches Arbli, the first FDA-approved liquid losartan, expanding hypertension treatment access across US healthcare institutions.

Scienture Holdings, Inc. announced GPO agreements for its new drug, Arbli, providing access to over 2,500 healthcare institutions and plans to expand further.